Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Bruker Corporation BRKR

Healthcare — Medical Devices
Dividend Champion (5y)
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
3.61
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — 1 1 3 1 1 1 1 1 1 2 1
Insider Ownership
27.12%

Capital & Financial Ratios

Market Cap
9,620.00
Revenue
3,499.60
Net Income
(64.50)
Free Cash Flow
93.90
Net Debt
1,639.90
Current Ratio
1.85
Debt/Equity
0.76
P/E ratio
0.00
P/S ratio
2.67
P/B ratio
3.90
Past 5Y EPS Growth
(9.69%)
This Y EPS Growth
16.06%
Next Y EPS Growth
12.78%
Next 5Y EPS Growth
15.05%
in millions of $

Dividends

Payout Ratio
0.09
Annual Dividend Rate
0.20
Annual Dividend Yield
0.21%
total individual payouts
2028 ‡‡‡‡‡
2027 ‡‡‡‡‡
2026 0.33
—
—
—
2025 0.20
—
—
—
—
2024 0.20
—
—
—
—
2023 0.20
—
—
—
—
2022 0.20
—
—
—
—
2021 0.16
—
—
—
—
2020 0.16
—
—
—
—
2019 0.16
—
—
—
—
2018 0.16
—
—
—
—
2017 0.16
—
—
—
—
2016 0.16
—
—
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 488.30 183.40 298.80 184.90
Receivables 492.00 565.50 544.90 545.90
Inventory 968.30 1,067.80 1,094.60 1,120.10
Other 215.60 236.50 274.20 374.10
2,164.20 2,053.20 2,212.50 2,225.00
2023 2024 2025 Q'26
Payables 202.70 234.10 215.90 200.20
ST’ Debt 121.20 32.50 16.60 10.10
Other 478.20 576.50 605.40 549.80
1,202.10 1,281.30 1,279.20 1,204.70
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 823.40 838.50 — —
—
’25 801.40 797.40 860.50 977.20
3,436.50
’24 721.70 800.70 864.40 979.60
3,366.40
’23 685.30 681.90 742.80 854.50
2,964.50
’22 595.00 588.40 638.90 708.40
2,530.70
’21 554.70 570.80 608.90 683.50
2,417.90
’20 424.00 424.60 511.40 627.50
1,987.50
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 71.20 (77.40) — —
—
’25 65.00 (127.50) (33.20) 229.80
134.10
’24 21.80 1.10 38.40 190.00
251.30
’23 87.50 13.00 44.10 205.50
350.10
’22 77.80 (44.40) 69.50 171.50
274.40
’21 98.00 21.90 23.90 138.60
282.40
’20 35.00 11.80 82.40 203.00
332.20
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 47.00 (106.20) — —
—
’25 39.00 (148.80) (54.10) 207.20
43.30
’24 0.40 (23.50) 5.80 153.30
136.00
’23 73.20 (10.50) 17.40 163.10
243.20
’22 71.50 (61.20) 11.80 137.00
159.10
’21 74.50 0.50 9.20 111.10
195.30
’20 4.50 (8.40) 64.80 174.30
235.20
in millions of $

EPS

Mar Jun Sep Dec Year
’26 0.02 (0.41) — —
—
’25 0.11 0.05 (0.41) 0.10
(0.15)
’24 0.35 0.05 0.27 0.09
0.76
’23 0.52 0.39 0.60 1.41
2.90
’22 0.41 0.33 0.59 0.66
1.99
’21 0.37 0.38 0.57 0.50
1.81
’20 0.07 0.16 0.35 0.45
1.02

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

2.1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 48.42 53.79 48.07 28.53 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 83.69 84.84 94.86 64.64 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8,525 9,707 11,396 11,085 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.30 0.31 0.30 0.31 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,530.70 2,964.50 3,366.40 3,436.50 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 51.59% 51.05% 49.00% 45.91% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 413.90 544.20 206.90 22.00 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 16.36% 18.36% 6.15% 0.64% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 298.50 428.50 113.80 (8.30) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 88.80 114.90 183.80 220.30 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17.03 20.25 22.59 22.64 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 2.00 2.92 0.76 (0.15) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.85 2.39 1.69 0.88 ‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.78) (0.73) (0.77) (0.60) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 1.07 1.66 0.91 0.29 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.58 9.53 12.06 16.29 ‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 148.60 146.40 149.00 151.80 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 34.54 24.76 77.13 0.00 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.06 3.57 2.59 2.08 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.12 7.59 4.86 2.89 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.28 3.84 3.16 2.54 ‡‡‡‡ ‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 58.93 42.45 66.20 128.07 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 274.40 350.10 251.30 134.10 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (115.30) (106.90) (115.30) (90.80) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 159.10 243.20 136.00 43.30 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,198.90 962.10 771.90 933.30 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,219.20 1,281.50 2,094.30 1,869.10 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 573.70 793.20 1,910.90 1,570.30 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,125.70 1,394.60 1,797.10 2,473.50 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.17% 10.87% 2.25% (0.37%) — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 15.91% 12.48% 4.27% 1.05% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 26.84% 33.90% 7.09% (1.05%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Bruker Corporation (BRKR) is at a pivotal inflection point in scientific instrumentation, riding surging revenue of $3.37 billion in 2024 (up 13% YoY) driven by acquisitions like NanoString and PhenomeX, which supercharge proteomics, spatial biology, and AI-driven tools amid booming biotech demand. Despite profitability headwinds—net income plunging to losses through 2026 due to heavy R&D and integration costs—free cash flow remains positive, margins are poised for historical recoveries, and revenue projections climb steadily to $3.73 billion by 2027, signaling a strategic pivot toward explosive long-term growth.

The balance sheet stands resilient with equity up 79% to $1.8 billion, supporting M&A despite doubled debt, while insider conviction shines through the CEO’s $40 million share buy amid minor sells. Analysts forecast 34% upside (highs at 92%), undervalued at low PS and PB ratios, as BRKR taps $150 billion life sciences markets and EV battery tech— a disconnect from recent stock pullbacks that screams opportunity for patient investors eyeing 20-50% returns in the bio-revolution.

Read full commentary →

Bruker Corporation (BRKR) Latest News

News by impact score

Fine-tune

6 Sep

4 , 10:48 AM
Bruker Corporation bets on fusion energy technologies but faces investor caution and delayed market reaction. Bruker's fusion energy wager marks a major strategic shift likely to reshape long-term trajectory and sentiment.

4 Sep

3 , 2:00 AM
Bruker’s BEST division and Luvata signed a collaboration agreement to supply high-performance RRP superconductors for magnetic confinement fusion applications. Agreement expands Bruker’s superconductor supply role in emerging fusion projects without immediate large-scale revenue impact.

3 Sep

3 , 11:30 AM
BRKR shares rose 12.5% since last earnings report on positive investor reaction to results and outlook. Earnings-driven stock gains reflect moderate effects on near-term sentiment and positioning.

1 Sep

3 , 7:38 AM
Bruker (NASDAQ:BRKR) posts Q2 performance highlights in the research tools and consumables sector. Q2 results offer moderate insight into Bruker's financials and positioning but lack transformative details.

12 Aug

3 , 9:17 PM
Bruker Corporation fielded five notable analyst questions in its Q2 earnings call covering revenue trends, margin targets, product pipelines, and regional demand shifts in scientific instruments. Q2 earnings call questions offer moderate visibility into operational priorities and outlook that can influence near-term investor sentiment.

11 Aug

4 transcript www.fool.com, 1:00 PM
Bruker Corporation conducted its Q2 2026 earnings call, covering quarterly financial results, operational performance, and forward guidance. Q2 2026 earnings figures and guidance directly shape near-term valuation and investor positioning for BRKR.

3 , 7:00 AM
Bruker Corporation announced a strategic collaboration with Atinary Technologies to advance self-driving laboratories. Collaboration targets laboratory automation innovation with potential effects on Bruker's product development.

10 Aug

4 , 7:00 AM
Bruker Corporation announces majority investment in MIMETAS to advance human physiology-relevant drug discovery and development. Majority investment in MIMETAS gives Bruker new capabilities in organ-on-a-chip models that can materially expand its drug discovery offerings and growth trajectory.

5 Aug

3 , 4:11 AM
Bruker stock dropped 20% on Q2 loss from goodwill impairment despite higher sales. Q2 goodwill impairment loss signals acquisition issues that weigh on near-term financials and valuation.

3 , 1:12 AM
Bruker (BRKR) shares may trade 16% below fair value after Q2 results and 2026 guidance release. Q2 earnings and 2026 guidance can shift valuation perceptions and short-term market views on performance.

4 Aug

4 transcript , 5:01 PM
Bruker Corp reported Q2 2026 earnings with organic growth returning and margins surging. Returning organic growth and surging margins signal major positive shifts in financial performance and investor outlook.

4 investorshub.advfn.com, 11:23 AM
Bruker reports second-quarter 2026 results, with accelerating bookings for scientific instruments. Accelerating scientific instruments bookings point to stronger demand and revenue growth ahead.

3 app.moby.co, 5:31 PM
Bruker Corporation Q2 2026 earnings call covered financial results, operational updates and forward guidance for the company. Earnings call details provide updates on performance and outlook that moderately affect near-term investor views.

3 transcript www.marketbeat.com, 11:04 AM
Bruker Corporation reported Q2 financial results during its earnings call, covering revenue, earnings per share, segment performance, and forward guidance. Q2 earnings call supplies updated financials and outlook that can shift near-term investor sentiment and valuation.

3 , 10:30 AM
Bruker (BRKR) Q2 earnings key metrics are compared against estimates. Q2 earnings metrics versus estimates inform on financial performance and near-term market expectations.

3 , 8:25 AM
Bruker (BRKR) beat Q2 earnings estimates. Q2 earnings beat signals stronger financial results with moderate effect on performance outlook.

3 , 7:54 AM
Bruker reported Q2 CY2026 sales below analyst estimates, triggering an 11.9% stock price decline. Single-quarter sales miss drove immediate 11.9% stock drop but remains an isolated event unlikely to reshape long-term trajectory.

3 , 7:00 AM
Bruker Corporation reported its second quarter 2026 financial results. Quarterly earnings directly affect investor views on Bruker performance and valuation.

15 Jul

3 , 7:00 AM
Bruker acquires Metagenomic mNGS DISQVER® Platform to expand infection detection portfolio for pathogenic microorganisms in blood. Acquisition adds metagenomic sequencing to Bruker's diagnostics offerings with moderate market growth potential.

19 Jun

3 , 8:35 AM
Bruker Corporation stock rose 50.3% over the past year on the back of unspecified performance drivers. Year-long stock gains signal moderate ongoing strengths without evidence of transformative shifts.

10 Jun

3 Simply Wall St., 3:15 AM
Bruker expands diagnostics and energy-research tools portfolio with direct implications for shareholder value and company positioning. Portfolio expansion affects product offerings and market positioning without indicating transformative shifts.

6 Jun

4 www.marketbeat.com, 4:02 PM
Bruker Corporation reports accelerating orders from semiconductor and international markets, signaling a strategic pivot toward these growth drivers. Gaining semiconductor and overseas orders indicates major strategic momentum that can reshape revenue trajectory and investor outlook.

2 Jun

3 Business Wire, 11:24 AM
Bruker launches timsMRMS mass spectrometry platform for ultra-complex mixture analysis in the energy industry. New platform expands Bruker offerings into energy-sector applications with moderate competitive upside.

1 Jun

4 Business Wire, 7:00 AM
Bruker announces major strides in 4D proteomics performance, advances in intact and top-down functional proteoform analysis, and innovations in hybrid qual/quant 4D metabolomics to enable deeper disease biology insights. Major technological advances in core proteomics and metabolomics products strengthen Bruker's competitive positioning and growth prospects in life science instrumentation.

26 May

4 Simply Wall St., 5:15 PM
Bruker Corporation advances leadership in ultra-high-field preclinical MRI systems, strengthening competitive moat in scientific instruments and imaging technology. Ultra-high-field preclinical MRI leadership represents major product innovation that can materially improve Bruker's competitive position and long-term growth trajectory.

7 May

4 transcript www.fool.com, 11:00 AM
Bruker Corporation (BRKR) released its Q1 2026 earnings call transcript, covering financial results, operational updates, and forward guidance. Q1 2026 earnings transcript details financial performance and strategic outlook with potential to significantly sway investor sentiment and stock trajectory.

3 Zacks, 10:28 AM
Bruker Corporation (BRKR) stock rose after Q1 earnings and revenue beat expectations, though margins declined. Q1 earnings and revenue beat boosted stock price despite margin decline, moderately impacting financial performance and sentiment.

6 May

4 www.marketbeat.com, 10:55 AM
Bruker Corporation's Q1 earnings call highlighted revenue growth of 15%, raised full-year guidance, strong performance in life sciences and analytics segments, and updates on acquisitions and R&D investments. Q1 earnings results, raised guidance, and strategic updates signal significant positive momentum for BRKR's financial trajectory and investor sentiment.

4 Zacks, 7:45 AM
Bruker Corporation (BRKR) reported Q1 earnings per share of $0.74, surpassing the consensus estimate of $0.70, and revenue of $651.1 million, beating expectations of $644.2 million. Surpassing Q1 earnings and revenue estimates demonstrates strong financial performance, likely enhancing investor sentiment and stock trajectory.

4 StockStory, 6:47 AM
Bruker Corporation (NASDAQ:BRKR) reported strong sales in Q1 CY2026. Strong Q1 sales demonstrate robust financial performance likely to enhance investor sentiment and future market trajectory.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us